DOCSLIB.ORG

Gedeon Richter Annual Report Gedeon Richtergedeon • Annual Report • 2011

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Gedeon Richter Annual Report Gedeon Richtergedeon • Annual Report • 2011 GEDEON RICHTER ANNUAL REPORT GEDEON RICHTERGEDEON • ANNUAL REPORT • 2011 1901 2011 00Borito_annual_report_angol_2012_140_old.indd 1 3/25/12 2:29 PM Delivering quality therapy through generations 2011 01_angol_elso_resz_01_66.indd 1 3/26/12 2:23 PM 2 Contents CONTENTS Richter Group – Fact Sheet . 3 Consolidated Financial Highlights . 5 Chairman’s Statement . 7 Directors’ Report . 9 Information for Shareholders . 9 Shareholders’ Highlights . 9 Market Capitalisation . 9 Annual General Meeting . 10 Investor Relations Activities . 10 Dividend . 11 Information Regarding Richter Shares . 12 Shares in Issue . 12 Treasury Shares . 12 Registered Shareholders . 12 Share Ownership by Company Board Members . 13 Risk Management . 14 Corporate Governance . 16 Company’s Boards . 18 Board of Directors . 18 Executive Board . 21 Supervisory Committee . .22 Managing Director’s Review . 25 Operating Review . 29 Consolidated Turnover . 29 Markets – Pharmaceutical Segment . 31 Hungary . 32 International Sales . 34 European Union . 35 CIS . 37 USA . 38 Rest of the World . 38 Wholesale and Retail Activities . 39 Research and Development . 40 Female Healthcare . 42 Products . 46 Manufacturing and Supply . 50 Corporate Social Responsibility . 51 Environmental Policy . 51 Health and Safety at Work . 52 Work Health and Safety Management System . 52 Practical Implementation . 52 Community Involvement . 53 People . 54 Employees . 54 Recruitment and Individual Development . 55 Developing Leaders . 56 Remuneration and Other Employee Programmes . 56 Financial Review . 59 Key Financial Data . 59 Cost of Sales . 59 Gross Profit . 59 Operating Expenses . 60 Profit from Operations . 61 Net Financial Income . 61 Share of Profit of Associates . 62 Income Tax . 62 Profit for the Year . 62 Profit Attributable to Owners of the Parent . 62 Balance Sheet . 63 Cash Flow . 63 Capital Expenditure . 64 Treasury Policy . 65 Litigation Proceeding . 66 Consolidated Financial Statements . 68 Independent Auditor’s Report . 68 Notes to the Consolidated Financial Statements . 75 Appendices . 134 Consolidated Financial Record 2005-2011 . 134 Unconsolidated Financial Record 2005-2011 . 136 01_angol_elso_resz_01_66.indd 2 3/26/12 2:23 PM Richter Group – Fact Sheet • Gedeon Richter 2011 3 RICHTER GROUP – FACT SHEET Richter Group is active in two major business segments, primarily Pharmaceuticals comprising the research and development, manufacturing and marketing of pharmaceutical products, and it is also engaged in the Wholesale and retail of these products . In addition, there is a third group (’Other’) of companies comprising those members of the Group which provide auxiliary services to the former segments . Research, development, manufacturing and marketing of pharmaceutical products are the core activities of Richter and in this endeavour the Group is supported by a number of subsidiaries, joint ventures and associated companies . Manufacturing subsidiaries of the Group which operate in traditional markets together with a broad network of trading affiliates which ensure a strong market presence have together created the foundation for regional leadership and pan-European presence in the spe- cialty area of gynaecology . PARENT COMPANY DATA Headquarters . 1103 Budapest, Gyömrői út 19-21 ., Hungary Mail address . 1475 Budapest, Pf . 27 ., ngaryHu Phone . +36 1431 4000 Fax . +36 1260 4891 E-mail . posta@richter .hu Website . www .richter .hu Established . 1901 Main activity . Research, development, manufacturing and marketing of pharmaceutical products VAT Number . 10484878-2-44 . ..
Load more

Recommended publications
  • Molnár Melina – a Tőzsde És Ami Mögötte
    A Tőzsde és ami mögötte van Molnár Melina Budapesti Értéktőzsde Zrt. Budapesti Corvinus Egyetem, 2015. szeptember 30. Gondolatmenet A tőkepiac A tőzsdék szerepe a gazdaságban A tőkepiac szereplői Mi mozgatja az árakat, és mi a befektetőket? Hozam vs. kockázat 623 milliárd USD (1.) GDP: 134 milliárd USD 16 milliárd USD 73 milliárd USD (3.) 421 milliárd USD (2.) 24 milliárd USD (29.) Mi a tőzsde, és miért alakult ki? 4 | Pénzügyi piacok PÉNZÜGYI KÖZVETÍTŐK MEGTAKARÍTÓK FORRÁSIGÉNYLŐK • Háztartások • Háztartások • Állam • Állam • Vállalatok • Vállalatok Vállalatok növekedési forrásai BELSŐ KÜLSŐ FORRÁSOK FORRÁSOK Stratégiai Nyereség Bankhitel befektető Tulajdonosi tőke Támogatás TŐKEPIAC 6 | Pénzügyi piacok PÉNZÜGYI KÖZVETÍTŐK MEGTAKARÍTÓK FORRÁSIGÉNYLŐK • Háztartások • Háztartások • Állam • Állam • Vállalatok • Vállalatok Pénzügyi piacok PÉNZÜGYI KÖZVETÍTŐK MEGTAKARÍTÓK FORRÁSIGÉNYLŐK • Háztartások • Háztartások • Állam • Állam • Vállalatok • Vállalatok Mi a tőzsde és miért alakult ki? . Nagy földrajzi felfedezések . Első részvénytársaságok Finanszírozás és Kockázatmegosztás 1553 – Oroszország Társ., 1600 – Kelet-Indiai Társ.,1602 – Holland Kelet-Indiai Társaság, Amszterdami Tőzsde . Tőzsdék megalakulása 1566 – London 1602 – Amszterdam 1817 – New York 1864 – Budapesti Áru és Értéktőzsde A tőkepiac felépítése A Másodlagos Elsődleges piac piac VÁLLALAT TŐZSDE OTC Részvények Kötvények Csak Új értékpapír adásvétel Erős gazdaság VS virágzó tőkepiac Source: World Bank , 2012 11 | Erős gazdaság VS virágzó tőkepiac Source: World Bank
    [Show full text]
  • Hereinafter: the “Company”) Would Like to Inform Its Shareholders That Based on a Resolution No
    Payment of dividends by Chemical Works of Gedeon Richter Plc. The Chemical Works of Gedeon Richter Plc. (hereinafter: the “Company”) would like to inform its shareholders that based on a resolution No. 7/2021. 04. 15. of the Board of Directors acting in the competence of the AGM, in the case of common shares: 225% of the nominal value, that is HUF 225 per share will be paid as dividends - provided that the shareholders will not initiate the convocation of the AGM for the subsequent approval of the resolution on the annual report and the allocation of after-tax profits, pursuant to Section 9(6) of decree no. 502/2020 (XI.16.) of the Government of Hungary - pursuant to paragraph 7.11.1 of the Company’s Statutes, in a way that the Company will increase the payment, i.e. distribute the dividend after treasury shares among the shareholders entitled to dividend, in the proportion of their shares. The per share amount of dividend so increased will be established and published by the Company on June 1, 2021 on the website of the Budapest Stock Exchange and of the Company. The dividend is paid according to the following: Right to Dividends All natural and legal persons who own shares of the Company as of the below specified date according to the identification of ownership initiated by the Company and to be carried out in accordance with the Regulations of KELER Zrt., who have had their names registered in the Share Registry and who have rendered their identification data as required by the legislation at the Company’s disposal by way of their securities account keeper are entitled to dividends.
    [Show full text]
  • Memory Enhancers for Alzheimer's Dementia
    pharmaceuticals Review Memory Enhancers for Alzheimer’s Dementia: Focus on cGMP Ernesto Fedele 1,2,* and Roberta Ricciarelli 2,3,* 1 Department of Pharmacy, Section of Pharmacology and Toxicology, University of Genoa, 16148 Genova, Italy 2 IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy 3 Department of Experimental Medicine, Section of General Pathology, University of Genoa, 16132 Genova, Italy * Correspondence: [email protected] (E.F.); [email protected] (R.R.) Abstract: Cyclic guanosine-30,50-monophosphate, better known as cyclic-GMP or cGMP, is a classical second messenger involved in a variety of intracellular pathways ultimately controlling different physiological functions. The family of guanylyl cyclases that includes soluble and particulate en- zymes, each of which comprises several isoforms with different mechanisms of activation, synthesizes cGMP. cGMP signaling is mainly executed by the activation of protein kinase G and cyclic nucleotide gated channels, whereas it is terminated by its hydrolysis to GMP operated by both specific and dual-substrate phosphodiesterases. In the central nervous system, cGMP has attracted the attention of neuroscientists especially for its key role in the synaptic plasticity phenomenon of long-term potentiation that is instrumental to memory formation and consolidation, thus setting off a “gold rush” for new drugs that could be effective for the treatment of cognitive deficits. In this article, we summarize the state of the art on the neurochemistry of the cGMP system and then review the pre-clinical and clinical evidence on the use of cGMP enhancers in Alzheimer’s disease (AD) therapy. Although preclinical data demonstrates the beneficial effects of cGMP on cognitive deficits in AD animal models, the results of the clinical studies carried out to date are not conclusive.
    [Show full text]
  • Presentation
    IMPORTANCE OF CAPITAL MARKETS RICHÁRD VÉGH CEO and Chairman of Budapest Stock Exchange IOSCO ANNUAL CONFERENCE Budapest, May 10, 2018 SUCCESSFUL AND DEVELOPED COUNTRIES HAVE STRONG CAPITAL MARKET 70 CH NOR 60 Reduces the cost of long-term funding. USD) AUT 50 DK FIN SWE Cost-effective way 40 ISR UK of transferring capital thousand KOR between industries. 30 HUN POL Supports 20 CHN innovation. IDN 10 GDP/CAPITA ( GDP/CAPITA A more stable and IND resilient monetary 0 0% 50% 100% 150% 200% 250% system. MARKET CAPITALIZATION/GDP Source: OECD (2016), World Bank (2016) 2 STRONG AND IMPROVING ECONOMY 1 YEAR CDS CURVE PERFORMANCE OF INDICES BUMIX 200 300% +203% BUX 260% CETOP BUX 150 BUMIX +133% 220% DJ STOXX 600 100 DAX 180% 140% 50 100% 0 60% 2013 2018 2015 2018 DEBT TO GDP (%) GDP GROWTH (%) CPI (%) UNEMPLOYMENT RATE (%) 76,6 76,7 76,0 4,3 6,2 73,6 4,0 4,1 4,0 2,9 3,0 2,5 5,1 3,2 2,4 4,2 MAIN MAIN 3,6 2,2 3,1 2,8 INDICATORS 0,9 0,5 14 15 16 17 15 16 17 18* 19* 20* 15 16 17 18* 19* 20* 15 16 17 18* 19* 20* 3 *Forecast Source: Bloomberg, MNB, AKK, MND STRONG GROWTH IN HOUSEHOLD WEALTH – BUT CONSERVATIVE SAVING STRUCTURE Institutional side Retail side ASSETS IN HUNGARIAN MUTUAL BREAKDOWN OF HUNGARIAN FUNDS 2018 Q1 HOUSEHOLD’S WEALTH (billion HUF) Other investment 18% (4% domestic, Shares in Stock Exchanges 14% foreign) 1,6% 48 000 Property Bank deposit 45 000 42 000 Stock T-bill 9266 39 000 billion HUF 36 000 Corp.
    [Show full text]
  • Gedeon Richter
    Gedeon Richter Location: Europe Partner: FirePro Hungary Application: Archive Industry: Pharmaceuticals Why FirePro? FirePro condensed aerosol technology is engineered to suppress multiple classes of fire even in the presence of physical obstacles. But even more Gedeon Richter Plc. is a European importantly, the fast-released fire suppression agent is also capable to multinational pharmaceutical and contain fire efficiently while limiting direct and collateral damage to the biotechnology company with HQs in protected assets. FirePro’s eco-friendly fire suppression, low maintenance Budapest, Hungary. It is one of the largest requirements and 15-year lifespan are also some of the characteristics that pharmaceutical companies in Central set it apart from other technologies. Finally, the system can also be easily and Eastern Europe with worldwide connected to the Building Management System (BMS) to offer real time operations in over 40 countries. Gedeon status feedback. was established by Gedeon Richter, a pharmacist, in 1901. Today the company holds a primary listing on the Budapest Stock Exchange and is a major constituent Risks Involved & Consequences of the BUX blue chip Index. Archives are prone to a number of fire hazards even under the watchful eye of vigilant operators. Fire hazards originate from violations of fire safety rules, inadequate maintenance of the structure itself and human negligence. Other hazards include arson and electrical failures such as short-circuits and The Task overloading of electrical installations. Fire incidents in these archives are catastrophic due to the destruction of records and the intellectual property Design and commission an automatic fire of the organization. If not properly confronted, fire damage to archival suppression system for the protection of a collections can be permanent and irreparable.
    [Show full text]
  • Corporate Presentation Investor Relations, April 2016 General Information
    STADA Corporate Presentation Investor Relations, April 2016 General information By making use of this document the reader acknowledges and agrees to the following: We accept no liability arising from the use of this document. STADA Arzneimittel AG, Bad Vilbel (hereinafter “STADA”), has made every effort to make sure that this document contains correct and up-to- date information. STADA accepts no responsibility for and makes no guarantee whatsoever in respect of currentness, accuracy and completeness of the information and assumes no obligation to update, complete or correct this information. The anticipated opportunities and risks to STADA’s activities have been described in detail in the Executive Board’s management reports in the annual reports. Current possible opportunities and risks are discussed in the respective interim report. STADA’s performance indicators are party influenced by one-time special effects and/or effects not arising from the operating business. Disclosure of key figures adjusted for these effects (so called “pro forma” key figures) by STADA is only to provide a supplement to the recorded IFRS key figures for a transparent comparison to a relevant period from the previous year. All text, pictures, trademarks, and other information contained in this document are subject to the copyright of STADA or subject to rights acquired from third parties. Trademark protection may apply even for preparations not indicated as trade marks. This document may not be reproduced in whole or in part without the express written consent of STADA. Any disputes arising out of or in connection with the content of this document, insofar as they are directed against STADA, shall be subject to German law, without prejudice to mandatory provisions of foreign law.
    [Show full text]
  • Equity Note: Zwack Unicum
    EQUITY RESEARCH – ZWACK UNICUM EQUITY NOTE: ZWACK UNICUM Recommendation: HOLD (unchanged) Target price (12M): HUF 17,083 (revised up) 15 Dec 2020 We maintain our HOLD recommendation for Zwack Unicum (Zwack HB; ZWCG.BU) with a Equity Analyst: Orsolya Rátkai new 12M target price of 17,083 HUF/share, revised up from previous 15,407 HUF/share. With better-than-expected revenue and profit figures in the July-September period, Phone: +36 1 374 7270 Zwack gave evidence of its ability to swiftly recover once things normalize. However, it is mild comfort regarding the current business year. The second-wave restrictions Email: implemented in November, hitting on-the-site consumption, endanger on-trade sales [email protected] again as half of Zwack's revenues come from the restaurant industry. The present restrictions can also be a drag on retail sales of spirits even in the Christmas season as festivities are expected to be disallowed. However, covid vaccines are within reach, which is expected to totally change the landscape. With mass vaccination starting up next year, business as usual may return by the middle of the year/second half of 2021. Considering this, we updated our free cash- flow valuation and dividend discount models, and shifted the forecast horizon by one year. Uncertainties on short-term forecast are still high and the schedule of vaccination in Hungary is yet to be published, adding considerable downside risks to our forecast. On the other hand, if immunization proceeds as it is hoped, domestic tourism and restaurant industry is expected to recover quickly and Zwack will benefit from this development.
    [Show full text]
  • Review on Vinpocetine
    Review Article ISSN: 0976-7126 CODEN (USA): IJPLCP Dubey et al., 11(5):6590-6597, 2020 [[ Review on Vinpocetine Anubhav Dubey*, Neeraj Kumar, Ashish Mishra, Yatendra Singh and Mamta Tiwari 1, Department of Pharmacology, Advance Institute of Biotech and Paramedical Sciences Kanpur (U.P.) - India Abstract Article info Vinpocetine is a synthetic ethyl ester of apovincamine. It is extracted from the periwinkle plant. Vincamine is extracted from either Received: 12/03/2020 the seeds of Voacanga-Africana or the leaves. Vinpocetine is an herbal supplement used to treat various neurological disorders such as Revised: 29/04/2020 Alzheimer’s and Parkinson’s disease. Vinpocetine has also anti- inflammatory, analgesics, antioxidant property and treat various thinking Accepted: 26/05/2020 and memory problem. The drug has neuroprotective property thus it is used for memory impairment. Vinpocetine drug dilates blood vessels and © IJPLS promotes cerebral blood flow. Pharmacodynamics, Pharmacokinetic and adverse effects were discussed. www.ijplsjournal.com Keywords: Vincamine, neuroprotective, memory enhancement and cerebral blood flow Voacanga-Africana Introduction Vinpocetine was prepared under the trade name possible mechanism by which cerebral ATP levels cavinton in 1978[1], vinpocetine widely used in seemed to be increased after administration of the Germany, Russia, Japan, Hungar for the treatment compound. [3] of the cerebrovascular related disorder. Modern lifestyle has raised life hope but also Vinpocetine is a semi-synthetic derivative increase chronic harm full disease, therefore, obtained from vincamine alkaloid. Vincamine increasing chronic Pharmaceutical usage, it is also present in the aerial part of the vinca minor and called some time nootropic agent meaning plant belongs to the Apocynaceae family.
    [Show full text]
  • Morningstar Indexes Correlation
    Morningstar Indexes Correlation Learn More Morningstar Indexes capture a complete set of global investment opportunities, as demonstrated by their high degree indexes.morningstar.com of correlation to the industry’s major indexes. Each Morningstar Index can be used as discrete building blocks for Contact Us asset allocation and portfolio construction analysis. [email protected] North America +1 312 384 3735 EMEA +44 20 3194 1082 Morningstar Index 3rd Party Index Correlation Australia +61 2 9276 4446 Hong Kong +65 6340 1285 Equity Japan +813 5511 7580 US Style 10 yr Korea +82 2 3771 0721 Morningstar US Large Core MSCI US Large Cap 300 0.98 Singapore +65 6340 1285 Russell 1000 TR USD 0.98 S&P 500 TR USD 0.99 Morningstar US Large Growth MSCI US Large Cap Growth 0.99 S&P 500 Growth TR USD 0.98 Russell 1000 Growth TR USD 0.99 Morningstar US Large Value MSCI US Large Cap Value 0.99 Russell 1000 Value TR USD 0.98 S&P 500 Value TR USD 0.98 Morningstar US Mid Core MSCI US Mid Cap 450 1.00 Russell Mid Cap TR USD 0.99 S&P Mid Cap 400 0.99 Morningstar US Mid Growth MSCI US Mid Cap Growth 0.99 S&P Mid Cap 400 Growth 0.98 Russell Mid Cap Growth TR USD 0.99 Morningstar US Mid Value MSCI US Mid Cap Value 0.99 S&P MidCap 400 Value TR USD 0.97 Russell Mid Cap Value TR USD 0.99 Morningstar US Small Core MSCI US Small Cap 1750 1.00 Russell 2000 0.99 S&P SmallCap 600 TR USD 0.98 Morningstar US Small Growth MSCI US Small Cap Growth 0.99 S&P SmallCap 600 Growth 0.99 Russell 2000 Growth TR USD 0.99 Morningstar US Small Value MSCI US Small Cap Value 0.99 Russell 2000 Value TR USD 0.98 S&P SmallCap 600 Value TR USD 0.97 Morningstar US Core Russell 3000 0.99 S&P 500 0.99 Morningstar US Growth Russell 3000 Growth 0.99 S&P United States BMI Growth TR USD 0.99 Morningstar US Value Russell 3000 Value 0.99 S&P United States BMI Value TR USD 0.99 ©2019 Morningstar, Inc.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • The Use and Impact of Cognitive Enhancers Among University Students: a Systematic Review
    brain sciences Systematic Review The Use and Impact of Cognitive Enhancers among University Students: A Systematic Review Safia Sharif 1 , Amira Guirguis 1,2,* , Suzanne Fergus 1,* and Fabrizio Schifano 1 1 Psychopharmacology, Substance Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield AL10 9AB, UK; [email protected] (S.S.); [email protected] (F.S.) 2 Institute of Life Sciences 2, Swansea University, Swansea SA2 8PP, Wales, UK * Correspondence: [email protected] (A.G.); [email protected] (S.F.) Abstract: Introduction: Cognitive enhancers (CEs), also known as “smart drugs”, “study aids” or “nootropics” are a cause of concern. Recent research studies investigated the use of CEs being taken as study aids by university students. This manuscript provides an overview of popular CEs, focusing on a range of drugs/substances (e.g., prescription CEs including amphetamine salt mixtures, methylphenidate, modafinil and piracetam; and non-prescription CEs including caffeine, cobalamin (vitamin B12), guarana, pyridoxine (vitamin B6) and vinpocetine) that have emerged as being misused. The diverted non-prescription use of these molecules and the related potential for dependence and/or addiction is being reported. It has been demonstrated that healthy students (i.e., those without any diagnosed mental disorders) are increasingly using drugs such as methylphenidate, a mixture of dextroamphetamine/amphetamine, and modafinil, for the purpose of increasing their alertness, concentration or memory. Aim: To investigate the level of knowledge, perception and impact of the use of a range of CEs within Higher Education Institutions.
    [Show full text]
  • Potential Herb–Drug Interactions in the Management of Age-Related Cognitive Dysfunction
    pharmaceutics Review Potential Herb–Drug Interactions in the Management of Age-Related Cognitive Dysfunction Maria D. Auxtero 1, Susana Chalante 1,Mário R. Abade 1 , Rui Jorge 1,2,3 and Ana I. Fernandes 1,* 1 CiiEM, Interdisciplinary Research Centre Egas Moniz, Instituto Universitário Egas Moniz, Quinta da Granja, Monte de Caparica, 2829-511 Caparica, Portugal; [email protected] (M.D.A.); [email protected] (S.C.); [email protected] (M.R.A.); [email protected] (R.J.) 2 Polytechnic Institute of Santarém, School of Agriculture, Quinta do Galinheiro, 2001-904 Santarém, Portugal 3 CIEQV, Life Quality Research Centre, IPSantarém/IPLeiria, Avenida Dr. Mário Soares, 110, 2040-413 Rio Maior, Portugal * Correspondence: [email protected]; Tel.: +35-12-1294-6823 Abstract: Late-life mild cognitive impairment and dementia represent a significant burden on health- care systems and a unique challenge to medicine due to the currently limited treatment options. Plant phytochemicals have been considered in alternative, or complementary, prevention and treat- ment strategies. Herbals are consumed as such, or as food supplements, whose consumption has recently increased. However, these products are not exempt from adverse effects and pharmaco- logical interactions, presenting a special risk in aged, polymedicated individuals. Understanding pharmacokinetic and pharmacodynamic interactions is warranted to avoid undesirable adverse drug reactions, which may result in unwanted side-effects or therapeutic failure. The present study reviews the potential interactions between selected bioactive compounds (170) used by seniors for cognitive enhancement and representative drugs of 10 pharmacotherapeutic classes commonly prescribed to the middle-aged adults, often multimorbid and polymedicated, to anticipate and prevent risks arising from their co-administration.
    [Show full text]